Trial Profile
A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent to Subjects With Refractory Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sonepcizumab (Primary)
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- Sponsors Lpath
- 11 Oct 2016 Efficacy and safety results (n=40) published in the Cancer.
- 19 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 20 May 2015 According to an Lpath media release. status changed from active, no longer recruiting to completed.